Omniox
IND-stage biotechnology company developing a heme-binding protein platform into engineered oxygen-delivery biologics intended to selectively oxygenate pathologically hypoxic tissues. Activities described include protein engineering, preclinical and IND-stage development, process and analytical development, manufacture of clinical material, and compliance with NIH/PHS financial conflict-of-interest requirements. The company has received grant funding from multiple public and private research funders.
Industries
Nr. of Employees
small (1-50)
Omniox
San Carlos, California, United States, North America
Patents
Products
Heme-binding protein-based oxygen-delivery therapeutics
Therapeutic biologics derived from a heme-binding protein platform, engineered to carry and selectively release oxygen in pathologically hypoxic tissues.
H-NOX
A unique, stable and non-reactive heme-binding protein family with tunable affinity for oxygen, designed for different levels of physiologic oxygen need.
OMX biologics
OMX biologics are engineered to deliver oxygen safely to hypoxic tissues, where abnormally low oxygen levels drive disease pathology and worsen patient outcomes. They restore normal tissue function with the potential for improved outcomes and patient cures.
Heme-binding protein-based oxygen-delivery therapeutics
Therapeutic biologics derived from a heme-binding protein platform, engineered to carry and selectively release oxygen in pathologically hypoxic tissues.
H-NOX
A unique, stable and non-reactive heme-binding protein family with tunable affinity for oxygen, designed for different levels of physiologic oxygen need.
OMX biologics
OMX biologics are engineered to deliver oxygen safely to hypoxic tissues, where abnormally low oxygen levels drive disease pathology and worsen patient outcomes. They restore normal tissue function with the potential for improved outcomes and patient cures.
Services
In-house development of heme-binding protein platform candidates and preclinical evaluation toward clinical candidacy.
Process design, analytical characterization, and manufacture of clinical trial material for therapeutic candidates.
Implementation of financial conflict-of-interest policies, investigator training and disclosure/reporting processes aligned with NIH/PHS requirements.
In-house development of heme-binding protein platform candidates and preclinical evaluation toward clinical candidacy.
Process design, analytical characterization, and manufacture of clinical trial material for therapeutic candidates.
Implementation of financial conflict-of-interest policies, investigator training and disclosure/reporting processes aligned with NIH/PHS requirements.
Expertise Areas
- Oxygen-delivery biologics development
- Protein engineering and molecular design
- Preclinical and IND-enabling development
- Clinical materials process and analytical development (CMC)
Key Technologies
- Heme-binding protein platforms
- Engineered oxygen carrier design
- Protein engineering
- Structural biology
News & Updates
Received grants and other funding from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors.
Received grants and other funding from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors.